A Retrospective Study of Time to Relapse following Guselkumab Withdrawal in Patients with Psoriasis

Autor: Jia-Yi Zhuang, Fang-Fei Zhang, Yuan-Qiu Zhong, Yong-Feng Chen
Rok vydání: 2023
Předmět:
Zdroj: Dermatologic Therapy. 2023:1-5
ISSN: 1529-8019
1396-0296
2000-0413
DOI: 10.1155/2023/8466545
Popis: Background. Psoriasis is a chronic immune-mediated skin disease requiring long-term management. However, for various reasons such as financial issues, treatment cessation is common among psoriasis patients who have achieved clinical remission. Currently, only few studies have assessed the time to relapse after guselkumab withdrawal in the real-world setting. Objective. The study aimed at assessing the time to relapse after remission following guselkumab discontinuation in patients with moderate-to-severe plaque psoriasis in the real-world setting. Materials and Methods. Eligible adult moderate-to-severe plaque psoriasis patients received at least 2 doses of administration of guselkumab treatment between March 2020 and March 2022 were enrolled. The study included patients who achieved PASI P < 0.05 ). Compared with patients with PASI P < 0.001 ). Conclusions. Guselkumab provides durable maintenance of response after discontinuation of therapy in the real-world setting. Higher PASI score at relapse was associated with longer time to relapse. This trial is registered with Chinese Clinical Trial Registry: ChiCTR2000041398.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje